Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b trial

This article was originally published here

SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity. According to the company, the SENS-111 was

The post Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply